[go: up one dir, main page]

AR034518A1 - Incremento en la administracion transdermica de un farmaco - Google Patents

Incremento en la administracion transdermica de un farmaco

Info

Publication number
AR034518A1
AR034518A1 ARP020102283A ARP020102283A AR034518A1 AR 034518 A1 AR034518 A1 AR 034518A1 AR P020102283 A ARP020102283 A AR P020102283A AR P020102283 A ARP020102283 A AR P020102283A AR 034518 A1 AR034518 A1 AR 034518A1
Authority
AR
Argentina
Prior art keywords
prodrug
preferred
steroid
vehicle
steroidal
Prior art date
Application number
ARP020102283A
Other languages
English (en)
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26970627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR034518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharma filed Critical Noven Pharma
Publication of AR034518A1 publication Critical patent/AR034518A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición para administración transdérmica resultante de una mezcla incluye una cantidad eficaz para uso terapéutico de un fármaco que contiene un fármaco principal y un profármaco, y un vehículo aceptable para uso farmacéutico. El fármaco principal y el profármaco se encuentran presentes cada uno en una cantidad suficiente para tener un efecto farmacológico. En una realización preferida, la mezcla incluye una cantidad eficaz en términos terapéuticos de un agente con actividad farmacéutica que incluye un esteroide correspondiente y un derivado esteroidal, y un vehículo para el agente con actividad farmacéutica. El esteroide y el derivado esteroidal correspondiente se encuentran presentes en una relación ponderal entre 10:1 y 1:10 esteroide; derivado esteroidal correspondiente. En una realización preferida la relación es entre 6:1 y 1:6. En una realización preferida, el derivado esteroidal correspondiente es un éster esteroidal. En otra realización preferida, el vehículo es un polímero que incluye un adhesivo sensible a la presión. En otra realización preferida, el fármaco principal es un inhibidor de ACE tal como ramipril y el profármaco es un profármaco inhibidor de ACE tal como ramipril etil- y/o metiléster.
ARP020102283A 2001-06-18 2002-06-18 Incremento en la administracion transdermica de un farmaco AR034518A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29838101P 2001-06-18 2001-06-18
US94810701A 2001-09-07 2001-09-07

Publications (1)

Publication Number Publication Date
AR034518A1 true AR034518A1 (es) 2004-02-25

Family

ID=26970627

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102283A AR034518A1 (es) 2001-06-18 2002-06-18 Incremento en la administracion transdermica de un farmaco

Country Status (22)

Country Link
US (6) US7867986B2 (es)
EP (1) EP1406633B1 (es)
JP (1) JP5506126B2 (es)
KR (1) KR100988542B1 (es)
CN (1) CN100391462C (es)
AR (1) AR034518A1 (es)
AT (1) ATE526973T1 (es)
AU (1) AU2002320038B2 (es)
BR (1) BR0210516A (es)
CA (1) CA2451043C (es)
CL (1) CL2008000489A1 (es)
DK (1) DK1406633T3 (es)
ES (1) ES2375105T3 (es)
IL (2) IL159415A0 (es)
MX (1) MXPA03011910A (es)
NO (1) NO335025B1 (es)
NZ (1) NZ530227A (es)
PT (1) PT1406633E (es)
RU (2) RU2358699C2 (es)
SA (1) SA02230192B1 (es)
TW (1) TWI277418B (es)
WO (1) WO2002102390A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
AU2002316053A1 (en) 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
JP4116447B2 (ja) 2001-05-01 2008-07-09 エイ．ブイ．トップチーブ インスティテュート オブ ペトロケミカル シンセシス ヒドロゲル組成物
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
DK1406633T3 (da) * 2001-06-18 2011-10-31 Noven Pharma Forbedret lægemiddeltilførsel i transdermale systemer
DE10211832A1 (de) * 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion
US20050058695A1 (en) * 2002-05-30 2005-03-17 Watson Pharmaccuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
CN1655794A (zh) * 2002-05-30 2005-08-17 沃特森药物公司 炔诺酮持续释放制剂及其有关方法
US8658201B2 (en) 2004-01-30 2014-02-25 Corium International, Inc. Rapidly dissolving film for delivery of an active agent
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006017807A2 (en) 2004-08-05 2006-02-16 Corium International, Inc. Adhesive composition
AU2012202197B2 (en) * 2004-08-05 2015-01-29 A.V. Topchiev Institute Of Petrochemical Synthesis Adhesive composition
US20060106004A1 (en) * 2004-11-12 2006-05-18 Brody Steven A Unique methods and formulations of bio-identical sex steroids for the treatment of pathophysiologic aberrations of menopause
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
JP5209433B2 (ja) * 2007-10-19 2013-06-12 日東電工株式会社 貼付製剤
US8231906B2 (en) 2008-07-10 2012-07-31 Noven Pharmaceuticals, Inc. Transdermal estrogen device and delivery
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
WO2011068722A1 (en) * 2009-12-01 2011-06-09 Noven Pharmaceuticals, Inc. Transdermal testosterone device and delivery
EP3064199B1 (en) 2010-04-02 2023-12-20 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20110245288A1 (en) 2010-04-02 2011-10-06 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
CN103189064B (zh) * 2010-09-06 2015-08-12 拜耳知识产权有限责任公司 具有高药物释放的低剂量透皮贴剂
WO2012092165A1 (en) * 2010-12-29 2012-07-05 Noven Pharmaceuticals, Inc. Transdermal drug delivery system comprising levonorgestrel acetate
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
TW201431554A (zh) 2012-12-28 2014-08-16 Noven Pharma 左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及乙烯雌二醇之經皮藥物遞送系統
JP6359032B2 (ja) 2012-12-28 2018-07-18 ノーヴェン ファーマシューティカルズ インコーポレイテッド 経皮薬物送達用のマルチポリマー組成物
WO2014159582A1 (en) 2013-03-14 2014-10-02 Noven Pharmaceuticals, Inc Amphetamine transdermal compositions with acrylic block copolymer
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
AR095260A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
GB201404021D0 (en) * 2014-03-05 2014-04-23 Lumina Adhesives Ab Low cytotoxity switchable adhesive compositions, medical dressings and skin coverings, and methods of treatment using same
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN107207929B (zh) * 2015-01-21 2020-03-06 东洋油墨Sc控股株式会社 粘着剂组合物及粘着片以及其制造方法
EP3283172A1 (en) 2015-04-14 2018-02-21 The Procter and Gamble Company Solid conditioning composition
EP3283044B1 (en) 2015-04-14 2021-11-10 The Procter & Gamble Company Surface treating conditioning composition
US20160304808A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Consumer Product Composition
WO2016168224A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
WO2016168243A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Process of making a consumer product composition
WO2016168246A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10329519B2 (en) 2016-10-19 2019-06-25 The Procter & Gamble Company Consumer product composition comprising a polyethyleneglycol carrier, silicone conditioner, and particulate spacer material
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1478501A (en) 1922-06-21 1923-12-25 Woodin William Anor Knife guide
SE7713618L (sv) * 1977-12-01 1979-06-02 Astra Laekemedel Ab Lokalanestetisk blandning
US4213978A (en) 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4585452A (en) * 1983-04-12 1986-04-29 Key Pharmaceuticals, Inc. Transdermal systemic dosage forms
US4585836A (en) 1984-10-29 1986-04-29 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product with improved lap-shear stability-II
US4584355A (en) 1984-10-29 1986-04-22 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product with improved lap-shear stability-I
US4591622A (en) 1984-10-29 1986-05-27 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product thereof
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4847250A (en) 1985-11-29 1989-07-11 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
ATE84714T1 (de) 1987-06-12 1993-02-15 American Cyanamid Co Transkutane verabreichung von pharmazeutika.
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5925372A (en) 1987-12-16 1999-07-20 Novartis Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5405486A (en) 1988-03-04 1995-04-11 Noven Pharmaceuticals, Inc. Apparatus for forming a transdermal drug device
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5073539A (en) 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
FR2664815B1 (fr) 1990-07-23 1994-11-04 Adir Systeme matriciel autoadhesif pour la liberation prolongee du piribedil par voie transcutanee.
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
US5622944A (en) 1992-06-12 1997-04-22 Affymax Technologies N.V. Testosterone prodrugs for improved drug delivery
EP0581587A3 (en) 1992-07-31 1995-05-17 Tanabe Seiyaku Co Base material for transdermal administration.
ES2199954T3 (es) 1992-11-09 2004-03-01 Neurogesx, Inc. Administracion transdermica de cetorolac.
WO1994016709A2 (en) * 1993-01-19 1994-08-04 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
CH691209A5 (de) * 1993-09-06 2001-05-15 Scherrer Inst Paul Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten.
DE4333595A1 (de) 1993-10-01 1995-04-06 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Arzneimitteln auf die Haut
JPH0827003A (ja) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
FR2730627B1 (fr) * 1995-02-17 1997-07-25 Marc Reynaud Renfort dentaire autobloquant
DE19512181C2 (de) 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US5702720A (en) 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
DE19548332A1 (de) 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US5849729A (en) 1995-12-26 1998-12-15 Hershey Foods Corporation Use of hydrolyzed cocoa butter for percutaneous absorption
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9621095D0 (en) 1996-10-09 1996-11-27 Imperial College Novel system
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
WO1998051283A1 (en) * 1997-05-14 1998-11-19 Galen (Chemicals) Limited Topical compositions
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US6136327A (en) 1997-12-01 2000-10-24 Alza Corporation Stereospecific delivery of a drug using electrotransport
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
DE19828274C2 (de) 1998-06-25 2002-11-28 Rottapharm Bv Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
BR0010166A (pt) 1999-04-30 2002-06-04 Millennium Pharm Inc Composto modulador de ace-2, composto inibidor de ace-2, métodos para o tratamento de um estado associado a ace-2 em um paciente e para inibir a hidrólise de um peptìdeo de marcação de ace-2, e, composição farmacêutica
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
PE20010404A1 (es) * 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
US6368618B1 (en) * 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
CA2386954C (en) 1999-10-29 2011-12-13 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
DE10033855A1 (de) 2000-07-12 2002-01-31 Hexal Ag Matrixkontrolliertes transdermales System mit Sulfonsäuresalz eines ACE-Hemmers
RU2165251C1 (ru) * 2000-09-06 2001-04-20 Федеральное государственное унитарное предприятие Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко Твердая лекарственная форма эналаприла и способ ее получения
DK1406633T3 (da) 2001-06-18 2011-10-31 Noven Pharma Forbedret lægemiddeltilførsel i transdermale systemer
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors

Also Published As

Publication number Publication date
US8110565B2 (en) 2012-02-07
ATE526973T1 (de) 2011-10-15
PT1406633E (pt) 2012-01-12
NO335025B1 (no) 2014-08-25
EP1406633A1 (en) 2004-04-14
CN1543349A (zh) 2004-11-03
WO2002102390A1 (en) 2002-12-27
EP1406633A4 (en) 2006-08-16
US7846916B2 (en) 2010-12-07
AU2002320038B2 (en) 2007-07-05
KR20040010747A (ko) 2004-01-31
ES2375105T3 (es) 2012-02-24
US20030152615A1 (en) 2003-08-14
SA02230192B1 (ar) 2008-12-20
NZ530227A (en) 2006-09-29
IL159415A0 (en) 2004-06-01
JP2005500299A (ja) 2005-01-06
CL2008000489A1 (es) 2008-04-11
TWI277418B (en) 2007-04-01
JP5506126B2 (ja) 2014-05-28
US20030152613A1 (en) 2003-08-14
US7456159B2 (en) 2008-11-25
NO20035645L (no) 2004-02-13
CN100391462C (zh) 2008-06-04
US8025898B2 (en) 2011-09-27
US20030152614A1 (en) 2003-08-14
KR100988542B1 (ko) 2010-10-20
DK1406633T3 (da) 2011-10-31
RU2008111710A (ru) 2009-10-10
US20030232073A1 (en) 2003-12-18
US20080167280A1 (en) 2008-07-10
RU2358699C2 (ru) 2009-06-20
US7879831B2 (en) 2011-02-01
IL159415A (en) 2012-03-29
RU2004101407A (ru) 2005-03-10
CA2451043C (en) 2011-02-15
RU2449766C2 (ru) 2012-05-10
CA2451043A1 (en) 2002-12-27
US20080167365A1 (en) 2008-07-10
NO20035645D0 (no) 2003-12-17
BR0210516A (pt) 2004-10-05
US7867986B2 (en) 2011-01-11
MXPA03011910A (es) 2004-06-03
EP1406633B1 (en) 2011-10-05
HK1064920A1 (en) 2005-02-08

Similar Documents

Publication Publication Date Title
AR034518A1 (es) Incremento en la administracion transdermica de un farmaco
ES2094906T3 (es) Composiciones para la administracion topica de agentes farmaceuticamente activos.
BR0015605A (pt) Composição e uso
ES2152979T3 (es) Sistema terapeutico transdermal que contiene estradiol.
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
BR0107869A (pt) Composições farmacêuticas eletrogiradas
NZ509418A (en) Pharmaceutical formulations for aerosols with two or more active substances
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
BR0013704A (pt) Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
FI914391A0 (fi) Sammansaettningar vilka foerstaerker hudens permeabilitet.
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
BR9805993A (pt) Composição farmacêutica de aerosol.
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
CO6150128A2 (es) Formulacion de nevirapina de liberacion prolongada
YU14394A (sh) Flaster sa aktivnom supstancom za davanje estradiola na kožu
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
WO2005001027A3 (en) Compositions for down-regulation of ccr5 expression and methods of use therefor
PE17897A1 (es) Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada

Legal Events

Date Code Title Description
FC Refusal